31. Motor function assessment in spinal muscular atrophy patients

Nguyen Thi Hang, Vu Chi Dung, Nguyen Ngoc Khanh

Main Article Content

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the survival motor neuron (SMN) gene on chromosome 5q13. The condition is characterized by generalized muscle weakness, atrophy, and ultimately, disability and death. The Hammersmith Infant Neurological Examination Section 2 (HINE-2), the Hammersmith Functional Motor Scale (HFMS), and the Revised Upper Limb Module (RULM) are commonly used to assess motor function in SMA patients. This study aimed to evaluate motor abilities using these assessment tools in 121 SMA patients with confirmed diagnoses at the Vietnam National Children's Hospital from January 2021 to August 2023. Results: The lowest median HINE-2 score was in the SMA I group (3 points), while the highest was in the SMA III group (22.5 points). Regarding the Hammersmith scale, the median scores for the SMA II and SMA III groups were 17 points and 41 points, respectively, with no difference between age groups. Similarly, on the RULM scale, the median scores for the SMA II and SMA III groups were 17 points and 26 points, respectively, regardless of age. Conclusion: The SMA I group had the lowest motor function scores, while the SMA II and SMA III groups demonstrated higher scores. Higher scores on the scales corresponded to greater motor abilities.

Article Details

References

1. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: Simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015-1023. doi: 10.1038/sj.ejhg.5201288
2. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979-84. doi: 10.1001/archneurol.2011.74
3. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-65. doi: 10.1016/0092-8674(95)90460-3
4. Pane M, Palermo C, Messina S, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696-e703. doi: 10.1212/WNL.0000000000006050
5. Pierzchlewicz K, Kępa I, Podogrodzki J, et al. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment. Child Neurology Open. 2021;8:1-9. doi: 10.1177/2329048X211008725
6. Vuillerot C. State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Archives de Pédiatrie. 2020;27:7S40-7S44. doi: 10.1016/S0929-693X(20)30276-1
7. Marika P, Giorgia C, Valeria A, et al. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. Ann Neurol. 2019;86(3);443-451. doi: 10.1002/ana.25533
8. Léna S, Anita G, Rita J, et al. Efficacy of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Real World Data from Hungarian Patients. Eur J Paediatr Neurol. 2020;27:37-42. doi: 10.1016/j.ejpn.2020.05.002
9. Pera M, Coratti G, Mazzone E, et al. Revised upper limb module for spinal muscular atrophy: 12 months changes. Muscle Nerve. 2019;59(4):426-430. doi: 10.1002/mus.26419
10. Stimpson  G, Ramsey D, Wolfe A, et al. 2-year change in revised Hammersmith Scale Scores in a large cohort of untreated paediatric type 2 and 3 SMA participants. J Clin Med. 2023;12(5):1920. doi: 10.3390/jcm12051920
11. Coratti G, Pera  MC, Montes J. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscul Disord. 2022;32(1):36-42. doi: 10.1016/j.nmd.2021.10.009